GNXAX
Price
$14.46
Change
-$0.01 (-0.07%)
Updated
Sep 11 closing price
Net Assets
21.36M
RSLEX
Price
$81.54
Change
+$0.26 (+0.32%)
Updated
Sep 11 closing price
Net Assets
91.39B
Interact to see
Advertisement

GNXAX vs RSLEX

GNXAX vs RSLEX Comparison Chart in %
View a ticker or compare two or three
VS
GNXAX vs. RSLEX commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNXAX is a Hold and RSLEX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RSLEX has more cash in the bank: 91.4B vs. GNXAX (21.4M). RSLEX pays higher dividends than GNXAX: RSLEX (0.61) vs GNXAX (0.00). GNXAX was incepted earlier than RSLEX: GNXAX (9 years) vs RSLEX (24 years). GNXAX (2.59) is less costly to investors than RSLEX (1.00). GNXAX is a more actively managed with annual turnover of: 114.00 vs. RSLEX (41.00). RSLEX has a lower initial minimum investment than GNXAX: RSLEX (250) vs GNXAX (2500). RSLEX annual gain was more profitable for investors over the last year : 8.96 vs. GNXAX (-17.08). RSLEX return over 5 years is better than : -9.27 vs. GNXAX (-20.32).
GNXAXRSLEXGNXAX / RSLEX
Total Expense Ratio1.651.00165%
Annual Report Gross Expense Ratio2.591.00259%
Fund Existence9 years24 years-
Gain YTD-17.78412.299-145%
Front Load6%N/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRAN/AN/A-
Net Assets21.4M91.4B0%
Annual Yield % from dividends0.000.61-
Returns for 1 year-17.088.96-191%
Returns for 3 years35.7437.5295%
Returns for 5 years-20.32-9.27219%
Returns for 10 yearsN/A83.16-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCVRX28.60N/A
N/A
Goldman Sachs Large Cp Val Insghts R
MABAX20.14N/A
N/A
BlackRock Large Cap Focus Value Instl
LGLUX58.91N/A
N/A
Lord Abbett Growth Leaders R5
MXMTX11.48N/A
N/A
Empower Small Cap Growth Investor
AIHHX6.70N/A
N/A
Aristotle Small/Mid Cap Equity I-2